Answers are grounded in this paper and cite their sources.
To the Editor—Antibody responses occur even in completely asymptomatic persons with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, the initial immune response is not as strong as in patients with more severe disease, and concerns about waning immunity have been raised [1]. With great interest we read the recent article by Yao et al [2]. In their cross-sectional study, 90% of patients still have detectable IgG antibodies against spike and nucleocapsid proteins and neutralizing antibodies against pseudovirus. However, they could not evaluate the dynamic changes of antibody due to their cross-sectional study design. We tried to demonstrate the kinetics of neutralizing antibodies at precise time points in asymptomatic infection confirmed by close monitoring, as well as symptomatic infection. The polymerase chain reaction (PCR)-positive individuals admitted to community treatment centers (CTC) in Korea were evaluated twice daily using a video-consultation system by physicians [3]. Consequently, the CTC provided a unique opportunity to conduct prospective studies on asymptomatic infection [1, 4]. The Institutional Review Boards of Seoul National University Hospital approved the study (IRB No. H-2004-158-1118). Written informed consent was obtained from all patients. The serologic responses 2 and 5 months after infection of a cohort of 7 PCR-confirmed asymptomatic persons and 17 patients with pneumonia were previously reported [1, 4]. We monitored 16 of these patients for 1 year, that is 7 asymptomatic persons, 6 patients with subtle pneumonia (infiltrations were observed only on the computed tomography), and 3 patients with apparent pneumonia (those observed on plain chest radiograph). Their plasma samples were collected at a 3 to 4-month interval. The clinical characteristics of the patients are summarized (Supplementary Table). Live virus microneutralization assay was performed as previously described [1, 4], using the BetaCoV/Korea/SNU01/2020 virus and 2-fold serially diluted plasma samples (from 2-fold to 4096-fold). We semiquantitatively measured anti-S1 (spike protein subunit-1) IgG against SARS-CoV-2 by commercial enzyme-linked immunosorbent assay (ELISA) kit (Euroimmun). All patients showed neutralizing antibody response up to 1 year after infection. In 2 patients, who had acute-phase neutralizing antibody titer > 1024, the titers declined ≥ 4-fold 1 year later. In the remaining 14 patients, who had acute-phase neutralizing antibody titer ≤ 1024, the titers declined < 4-fold 1 year later and remained detectable up to 1 year after infection. The neutralizing antibody titer waned during the first 6 months after infection, and the waning of antibody titers between 6 months and 1 year after infection was less steep (Figure 1A). One year after infection, all patients with apparent pneumonia had positive result in anti-S1 IgG ELISA, whereas 2 (33.3%) patients with subtle pneumonia and 2 (28.6%) asymptomatic persons had negative result. The kinetics of anti-S1 IgG production showed a similar pattern to that of neutralizing antibody titers (Figure 1B) Kinetics of antibody responses over 1 year after asymptomatic or symptomatic SARS-CoV-2 infection. A, Live virus neutralization assay results. The geometric mean titers in duplicate have been jittered vertically (ie, random noise added to prevent overplotting). B, S1 IgG ELISA OD ratio results. The cutoff between negative and borderline samples for the S1 ELISA was an OD ratio of 0.8. Red (A-C) denotes the patients with apparent pneumonia, blue (D-I) does the patients with subtle pneumonia, and green (J-P) does the asymptomatic patients. Abbreviations: ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; OD, optical density; S1, spike protein subunit 1; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Understanding the longevity of humoral immunity to SARS-CoV-2 is urgently needed to determine priority for vaccination and needs for booster vaccine in patients who have already experienced coronavirus disease 2019 (COVID-19). In a study from the United States, antibodies against SARS-CoV-2 declined more quickly than those reported for SARS-CoV-1, within 3–4 months after diagnosis, raising concerns about rapidly waning immunity [5]. Recent studies showed antibodies against SARS-CoV-2 remained stable over time, declining moderately over 6–8 months after infection [6]. With the present cohort of patients, we previously reported that neutralizing antibody response occurred even in asymptomatic persons, and the severity of illness was associated with higher neutralizing antibody responses in the early phase of the disease [1]. Our present study shows that these neutralizing antibodies persist for at least 1 year. In the patients with the early highest antibody titers, antibody titers waned during the first 6 months after infection but were maintained over the next 6 months; this pattern of antibody production is comparable to that seen in patients experiencing Middle East respiratory syndrome (MERS) [7]. The correlation between neutralizing antibody titers and anti-S1 IgG levels in the present study could be explained by the fact that the receptor-binding domain in the S1 region is a main target of neutralizing antibodies [8]. The anti-S1 IgG ELISA showed negative results 1 year after infection in some patients with subtle pneumonia and asymptomatic persons. Positive rates in serologic assays could be different according to immunoassay methods or manufacturers [9]. Indeed, the anti-S pan-Ig assay (Roche Diagnostics) showed all positive results 1 year after infection, even in asymptomatic patients in the present study (data not shown). Although reinfection of SARS-CoV-2 has been occasionally reported, most cases of reinfection were usually milder, explained by priming of the adaptive immune response [10]. Taken together with other studies showing persistent immune memory [6], our study supports the concept that protective immunity against reinfection of SARS-CoV-2 may persist for over 1 year, even in asymptomatic infection. Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. Acknowledgments. We appreciated Kyung Sook Ahn, MD, Director of Gyeongsan City Health Center, for the administrative support; and Areum Jo, Su Jin Choi, Seoul National University Hospital Biomedical Research Institute, and Mee Kyung Ko, Pusan National University Hospital Biomedical Research Institute, for technical support. Disclaimer. The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Financial support. This work was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) and funded by the Korean government (MSIT) (grant number 2021M3A9I2080498). Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
No takes yet. Share an insight, caveat, or question.
Choe et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: